PHIO PHARMACEUTICALS CORP.
Income Statement
| Line Item | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $21.0K | $138.0K | $15.0K | $19.0K | $34.0K | $399.0K | $97.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $3.7M | $4.3M | $4.3M | $5.4M | $5.4M | $6.9M | $17.7M | $10.5M |
| SG&A Expense | $5.1M | $4.7M | $3.2M | $4.0M | $3.6M | $3.3M | $3.7M | $2.6M |
| Operating Income | $-8.8M | $-9.0M | $-7.4M | $-14.1M | $-9.0M | $-10.2M | $-20.9M | $-13.0M |
| Operating Margin | — | -42,795.2% | -5,336.2% | -93,746.7% | -47,447.4% | -30,108.8% | -5,250.4% | -13,376.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-8.8M | $-8.9M | $-7.4M | $-14.1M | $-9.0M | $-10.2M | $-20.9M | $-12.9M |
| Income Tax Expense | $0 | $0 | $0 | $-1.6M | $0 | $0 | $0 | — |
| Net Income | $-8.8M | $-8.9M | $-7.4M | $-12.5M | $-9.0M | $-10.2M | $-20.9M | $-12.9M |
| Net Margin | — | -42,419.0% | -5,333.3% | -83,013.3% | -47,336.8% | -30,067.6% | -5,244.4% | -13,278.4% |
| EPS (Basic) | $-0.08 | $-0.81 | $-2.39 | $-0.23 | $-0.68 | $-0.09 | $-0.12 | $-0.23 |
| EPS (Diluted) | $-0.08 | $-0.81 | $-2.39 | $-0.23 | $-0.68 | $-0.09 | $-0.12 | $-0.23 |
| Shares Outstanding (Basic) | 138.7M | 16.1M | 8.2M | 58.3M | 31.2M | 156.8M | 282.9M | 126.9M |
| Shares Outstanding (Diluted) | 138.7M | 16.1M | 8.2M | 58.3M | 31.2M | 156.8M | 282.9M | 126.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |